IP Library Granted Patent US 10,005,777
Granted Patent B2
US 10,005,777 · App. 15/588,410 · Granted Jun 26, 2018

Protein kinase C inhibitors and uses thereof

Inventors: Rajinder Singh (Belmont, CA); Matthew Duncton (San Bruno, CA); Jing Zhang (Mercer Island, WA); Salvador Alvarez (Fremont, CA); Kin Tso (San Francisco, CA); Sacha Holland (San Francisco, CA); Rose Yen (San Francisco, CA); Rao Kolluri (Foster City, CA); Thilo Heckrodt (San Francisco, CA); Yan Chen (Foster City, CA); Esteban Masuda (Menlo Park, CA); Hui Li (Santa Clara, CA); Donald G. Payan (Hillsborough, CA); Ryan Kelley (Pacifica, CA)
Assignee: Rigel Pharmaceuticals, Inc.
C07D471/04A61K31/506A61K31/538A61K31/5377A61K31/5383A61K31/5386A61K31/553C07D519/00C12N9/12C12Q1/485C12Y207/11013
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,005,777
App. No.
15/588,410
Granted
Jun 26, 2018
Kind
B2
Abstract

This disclosure concerns compounds which are useful as inhibitors of protein kinase C (PKC) and are thus useful for treating a variety of diseases and disorders that are mediated or sustained through the activity of PKC. This disclosure also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.

Claims (25)

1. A method for preparing an optically active compound, comprising contacting a racemic mixture of compounds of the formula:

with a lipase; wherein

R 1 , R 2 , R 3 , R 4 , R 5 , and R 6 are independently selected from hydrogen, alkyl, substituted alkyl, alkoxy, substituted alkoxy, acyl, acylamino, acyloxy, amino, substituted amino, aminoacyl, aminoacyloxy, oxyaminoacyl, azido, cyano, halogen, hydroxyl, carboxyl, carboxylalkyl, thiol, thioalkoxy, substituted thioalkoxy, aryl, aryloxy, hydroxyamino, alkoxyamino, nitro, —SO-alkyl, —SO-substituted alkyl, —SO-aryl, —SO-heteroaryl, —SO 2 -alkyl, —SO 2 -substituted alkyl, —SO 2 -aryl and —SO 2 -heteroaryl; or R 1 and R 2 together form an oxo group; or R 3 and R 4 together form an oxo group; or R 5 and R 6 together form an oxo group; and

R 7 , R 8 , R 9 , and R 10 are independently selected from hydrogen, alkyl, substituted alkyl, alkoxy, substituted alkoxy, acyl, acylamino, acyloxy, amino, substituted amino, aminoacyl, aminoacyloxy, oxyaminoacyl, azido, cyano, halogen, hydroxyl, carboxyl, carboxylalkyl, thiol, thioalkoxy, substituted thioalkoxy, aryl, aryloxy, hydroxyamino, alkoxyamino, nitro, —SO-alkyl, —SO-substituted alkyl, —SO-aryl, —SO-heteroaryl, —SO 2 -alkyl, —SO 2 -substituted alkyl, —SO 2 -aryl and —SO 2 -heteroaryl; or R 7 and R 8 together form an oxo group; or R 9 and R 10 together form an oxo group.

2. The method of claim 1 , wherein the lipase performs enzyme-catalyzed acylation of one of the stereoisomers in the racemic mixture.

3. The method of claim 1 , further comprising after the contacting, separating a stereoisomer from the racemic mixture.

4. The method of claim 3 , wherein the separating comprising separating the stereoisomer by chromatography.

5. The method of claim 3 , wherein the separated stereoisomer comprises an acyl group.

6. The method of claim 3 , wherein the separated stereoisomer comprises a hydroxyl group.

7. The method of claim 6 , further comprising converting the hydroxyl group of the separated stereoisomer to an amino group.

8. The method of claim 7 , further comprising contacting the separated stereoisomer with a compound of the formula:

to produce a compound according to the formula:

wherein

R 11 is selected from alkyl, substituted alkyl, hydroxy, alkoxy, substituted alkoxy, amino, substituted amino, carboxyl, carboxyl ester, cyano, halogen, acyl, aminoacyl, nitro, alkenyl, substituted alkenyl, alkynyl, and substituted alkynyl; and

Y 1 is selected from hydrogen, alkyl and substituted alkyl.

9. The method of claim 8 , further comprising contacting the compound according to the formula:

with a compound of the formula HNY 2 Ar 1 to produce a compound according to the formula:

wherein

Y 2 is selected from hydrogen, alkyl and substituted alkyl; and

Ar 1 is selected from aryl, substituted aryl, heteroaryl, and substituted heteroaryl.

10. The method of claim 9 , wherein the reaction is run in a polar aprotic or polar protic solvent.

11. The method of claim 9 , further comprising performing separation of isomers with chiral chromatography.

12. The method of claim 9 , further comprising performing separation of isomers with a resolution technique.

13. The method of claim 9 , wherein Ar 1 is aryl or substituted aryl.

14. The method of claim 9 , wherein Ar 1 is heteroaryl or substituted heteroaryl.

Assignments (3)
SECURITY INTEREST Recorded May 8, 2026
From: RIGEL PHARMACEUTICALS, INC.
To: MIDCAP FUNDING IV TRUST
Reel/Frame 075576/0880 →
SECURITY INTEREST Recorded Aug 25, 2022
From: RIGEL PHARMACEUTICALS, INC.
To: MIDCAP FINANCIAL TRUST
Reel/Frame 061327/0712 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 18, 2017
From: SINGH, RAJINDER; DUNCTON, MATTHEW; ZHANG, JING; ALVAREZ, SALVADOR; TSO, KIN; HOLLAND, SACHA; YEN, ROSE; KOLLURI, RAO; HECKRODT, THILO; CHEN, YAN; MASUDA, ESTEBAN; LI, HUI; PAYAN, DONALD G.; KELLEY, RYAN
To: RIGEL PHARMACEUTICALS, INC.
Reel/Frame 043030/0373 →
Continuity (5)
Continuation 15056535 · Feb 29, 2016
Division 13857028 · Apr 4, 2013
Provisional Application 61620232 · Apr 4, 2012
Provisional Application 61783647 · Mar 14, 2013
Related Publication 20180030050A1 · Feb 1, 2018